Last reviewed · How we verify
Azelaic acid foam
Azelaic acid reduces inflammation and bacterial growth in the skin by inhibiting mitochondrial enzymes and reducing reactive oxygen species production.
Azelaic acid reduces inflammation and bacterial growth in the skin by inhibiting mitochondrial enzymes and reducing reactive oxygen species production. Used for Rosacea, Acne vulgaris, Post-inflammatory hyperpigmentation.
At a glance
| Generic name | Azelaic acid foam |
|---|---|
| Also known as | Finacea Foam |
| Sponsor | Padagis LLC |
| Drug class | Topical antimicrobial and anti-inflammatory agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Azelaic acid is a dicarboxylic acid that exerts antimicrobial and anti-inflammatory effects on the skin. It inhibits the growth of Cutibacterium acnes and Staphylococcus epidermidis, while also reducing the production of inflammatory mediators and reactive oxygen species. The foam formulation enhances skin penetration and tolerability compared to other delivery forms.
Approved indications
- Rosacea
- Acne vulgaris
- Post-inflammatory hyperpigmentation
Common side effects
- Pruritus
- Erythema
- Burning sensation
- Scaling
Key clinical trials
- Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea (PHASE1)
- Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea (PHASE3)
- Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face (PHASE3)
- Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea (PHASE2)
- A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
- 21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation (PHASE1)
- Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation (PHASE1)
- Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azelaic acid foam CI brief — competitive landscape report
- Azelaic acid foam updates RSS · CI watch RSS
- Padagis LLC portfolio CI